Class IITerminatedD-1876-2019
Drug recall · October 2, 2019
Nucala (mepolizumab) Injection recall
Why: Temperature Abuse; Product stored and shipped outside of labeled storage requirements.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nucala (mepolizumab) Injection, 100 mg/mL Prefilled Syringe, Single-Dose, For subcutaneous use only, Rx Only, Manufactured by GlaxoSmithKline LLC, Philadelphia, PA 19112, Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0892-42.
- Lots / codes
Lot #: S25X, Exp. 03/31/21
- Quantity
- 38 syringes
- Company
- Cardinal Health dba Specialty Pharmaceutical Services, La Vergne, TN
- Distribution
- Nationwide in the U.S.
- Initiated
- September 6, 2019 · Voluntary: Firm initiated
- Classified
- September 20, 2019
- Reported
- October 2, 2019
- Ended
- October 8, 2020
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.